Nivolumab
Add to cart
Nivolumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody developed for therapeutic use.
How Nivolumab Works
Nivolumab is directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1/PCD-1). By targeting PD-1, nivolumab exhibits immune checkpoint inhibitory and antineoplastic activities.
What Does Nivolumab Do?
Nivolumab works to block PD-1, helping restore immune responses and promoting anti-tumor effects.
Who Makes Nivolumab?
Nivolumab is supplied by TargetMol.
Chemical Properties
| Molecular Weight | 146 kDa |
| CAS No. | 946414-94-4 |
References and Literature
1. Sundar R, et al. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar;7(2):85-96.2. Wang C, et al. In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates. Cancer Immunology Research. 2014 Sep;2(9):846-56.
